Ivermectin in Treatment of COVID-19

Zagazig University

Status and phase: Unknown; Phase 3; Phase 2

Conditions: COVID

Treatments: Drug: Ivermectin

Study type: Interventional

Funder types: Other

Identifiers

NCT04445311

ZU-IRB#6151/31-5-2020

Details and patient eligibility

About

confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

COVID-19 patients during period of the study more than 18 years old

Exclusion criteria

refuse to participate pregnancy or lactation hypersensitivity to ivermectin receive any drug with interaction with ivermectin

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

Ivermectin group

Experimental group

Description:

group that will receive ivermectin plus standard of care ttt

Treatment:

Drug: Ivermectin

Control group

No Intervention group

Description:

group that will receive standard of care ttt